Business Wire

Infinitas Launches Aureon Capital to Open Private Markets to Public Investors

30.3.2026 07:00:00 CEST | Business Wire | Press Release

Share

Infinitas Capital, the Swiss single family office led by Robin Lauber, today announces the launch of Aureon Capital, an investment company that will seek a listing on Nasdaq Stockholm. Its mission is to provide retail investors with access to private growth opportunities through a listed holding company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329050434/en/

Robin Lauber, Founder of Infinitas Capital

Aureon Capital is designed to open up Infinitas Capital’s private market ecosystem to public investors for the first time. Targeting an initial venture portfolio of between $100-200 million, the company will combine assets from Infinitas’ own portfolio alongside selected contributed assets from its wider network of family offices and UHNWIs. Additional capital will subsequently be raised for new investments. The company is currently working with a select group of partners across its network as it builds the initial portfolio.

Aureon’s strategy spans direct company investments, secondary opportunities and selected fund stakes, enabling Aureon Capital to source and deploy capital across the private markets lifecycle, from early-stage venture and growth companies to later-stage and pre-IPO opportunities, all through a single transparent, liquid structure. Public market investors will gain access to private companies, funds and other assets they would not typically be able to reach, without management fees or carry.

Aureon Capital’s planned listing on Nasdaq Stockholm reflects management’s confidence in the strength of the Swedish market and its active investor base.

Robin Lauber, Founder of Infinitas Capital, said:

“Some of the most compelling value creation today is happening in private markets, but access remains limited and capital is often locked up for long periods. Aureon Capital has been created to address that, by opening our private market ecosystem through a holding company structure that is simple, transparent and flexible.

“By bringing together assets from our own portfolio and from our network, we are building a vehicle that democratises access to venture and growth through a single liquid structure. Reaching a portfolio of sufficient size and attractiveness is important to ensure we create the right prerequisites for liquidity in the share and a platform that retail investors will want to be part of.”

Alexander Landorph, Head of Capital Markets at Infinitas Capital, added:

“Aureon Capital is being built to provide public market investors with access to a curated and diversified private market portfolio. Sweden is an attractive market for that model, with an active investor base and a proven desire for growth-focused investment companies.

“We are currently working to define the initial portfolio composition, with a focus on ensuring strong public market fit, fundraising and long-term value creation. Our ambition is to build a platform that can combine high-quality assets and long-term flexibility in how capital is raised and deployed.”

About Aureon Capital

Aureon Capital is an investment company seeking a listing on Nasdaq Stockholm. Created by Infinitas Capital, Aureon Capital is designed to open private markets to retail investors through a listed holding company. The company aims to provide access to a diversified portfolio spanning venture, growth and pre-IPO opportunities, combining private market exposure with public market liquidity.

For more information, visit https://www.aureoncapital.se/.

About Infinitas Capital

Infinitas Capital is the Lauber family’s single-family office, investing globally to challenge conventional paradigms and address key societal themes. The firm backs breakthrough companies, develops new living spaces through real estate strategies, and supports founders across the full company lifecycle – from pre-seed to IPO. When gaps in the market are identified, it selectively builds companies to address unmet needs where it holds a strong strategic advantage.

For more information, visit https://infinitas-capital.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260329050434/en/

Contacts

Media Enquiries
John West / Llewellyn Angus / Lily Pearce Rosewood

Email: media@infinitas-capital.com
Phone: +44 (0)20 7653 8702

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press Release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press Release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press Release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press Release

The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye